44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington
31 January 2005. Related: Conference reports.
ICAAC 44th Washington 2004
Tipranavir in treatment experienced patients: results from RESIST-1
31 January 2005. Related: Conference reports, Antiretrovirals.
Reverset: first data in patients with nucleoside resistance
31 January 2005. Related: Conference reports, Antiretrovirals.
Poor response with tenofovir and ddI backbone causes early study termination
31 January 2005. Related: Conference reports, Antiretrovirals.
Paradoxical CD4 response with tenofovir and ddI backbone
29 January 2005. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy
29 January 2005. Related: Conference reports, Antiretrovirals.
Limited stability of lopinavir/r (Kaletra) above 25°C
29 January 2005. Related: Conference reports, Antiretrovirals.
Atorvastatin requires dose reduction with tipranavir/r
29 January 2005. Related: Conference reports, PK and drug interactions.
Once-daily T-20 is less effective than twice daily: lower potency is related to C trough
29 January 2005. Related: Conference reports, Antiretrovirals.
Further genetic link to efavirenz absorption
29 January 2005. Related: Conference reports, Antiretrovirals.
Long-term response to FTC in children is similar to adults
29 January 2005. Related: Conference reports, Paediatric care.
Side effects update: hypersensitivity, heart, bones
29 January 2005. Related: Conference reports, Side effects.